Drugs targeting NEK7 exhibit the highest abundance, while LHX9 only attracts one substance named otenzepad, an acetylcholine receptor antagonist designed to treat cardiovascular diseases, which surprisingly shows effectiveness for NEK7 as well. The gene discussed is LHX9; the disease is cardiovascular disorder.